-

SHIFT4 PAYMENTS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Shift4 Payments, Inc. - FOUR

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 19, 2023 to file lead plaintiff applications in a securities class action lawsuit against Shift4 Payments, Inc. (NYSE: FOUR), if they purchased the Company’s securities between November 10, 2021 and April 18, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Pennsylvania.

What You May Do

If you purchased securities of Shift4 and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-four/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by October 19, 2023.

About the Lawsuit

Shift4 and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On April 19, 2023, Blue Orca Capital reported that “Shift4 [is], in reality, a roll-up of low-tech POS systems and payment processors which is substantially less profitable, generates far less cash, and is materially more levered than investors are led to believe,” and that in 2022, the Company “engaged in a string of highly questionable and hyper-aggressive accounting maneuvers seemingly designed to keep the stock afloat, from cash flow manipulation to inexplicable distributor acquisitions that enabled it to capitalize a major component of COGS [cost of goods sold].”

On this news, shares of Shift4 fell $5.95 per share, or 8.68%, to close at $62.59 per share on April 19, 2023.

The case is O'Meara v. Shift4 Payments, Inc., et al., No. 23-cv-03206.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit http://ksfcounsel.com/.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Industry:

Kahn Swick & Foti, LLC

NYSE:FOUR
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Acadia Healthcare Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Acadia Healthcare Company, Inc. - ACHC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Acadia Healthcare Company, Inc. (NasdaqGS: ACHC).On September 27, 2024, the Company disclosed the receipt of a voluntary request for information from the U. S. Attorney’s Office for the Southern District of New York as well as a grand jury subpoena from the United States District Court...

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engin...

Scotts Miracle-Gro Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of The Scotts Miracle-Gro Company - SMG

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into The Scotts Miracle-Gro Company (NYSE: SMG) (“Scotts” or the “Company”). On August 2, 2023, the Company disclosed disappointing financial results including a decline in quarterly sales for fiscal third quarter of 6%, a decline in gross margin by 420 basis points, as well...
Back to Newsroom